Search for a trial

A Phase 3, Randomized, Double-blind Active-controlled Study
Evaluating Momelotinib vs. Ruxolitinib in Subjects with Primary
Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential
Thrombocythemia Myelofibrosis (Post-PV/ET MF)

The primary objective of this study is:* The primary objective of this clinical trial will be to determine the efficacy of MMB compared with ruxolitinib as measured by splenic response rate at Week 24 (SRR24).The secondary objectives of this study…

Efficacy of post-operative pain management with intralesional ropivacaine after subacromial decompression

The researchquestions of this study are:1. What is the efficacy of treatment of postoperative pain after subacromial decompression with a subacromial catheter with ropivacaine versus placebo?2. What are the differences in costs per patient and in…

Reduction of Bone Morbidity using Oral Bisphosphonate in Fibrous Dysplasia of Bone

To evaluate the effect of the bisphosphonate risedronate (together with vitamin D and calcium or vitamin D calicum and phosphate in patients with renal phosphate wasting) on bone pain and the evolution of osteolytic bone lesions in patients with FD.

Pamidronate for pain in adult chronic nonbacterial osteitis (PAM-CNO): a randomized, double-blind, placebo-controlled trial

This study has been transitioned to CTIS with ID 2023-510309-16-00 check the CTIS register for the current data. The primary objective to demonstrate that in CNOpatients with pain 3-monthly treatment with pamidronate will result in significant…

Phase 3 Randomized, Placebo-Controlled Study to Assess Safety, Tolerability, and Efficacy of Garetosmab in Patients with Fibrodysplasia Ossificans Progressiva

This study has been transitioned to CTIS with ID 2023-508350-26-00 check the CTIS register for the current data. Primary ObjectiveThe primary efficacy objective of the study is to assess the effect of garetosmab (10 mg/kg) versus placebo on the…

Phase III, pivotal, multicentre, randomised, double-blind controlled Study to evaluate the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Early Stage Non Traumatic Osteonecrosis of the Femoral Head.

To determine the efficacy and safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of early stage non-traumatic osteonecrosis of the femoral head.